Biogen (BIIB) Other Non Operating Income (2009 - 2015)
Biogen (BIIB) posted quarterly Other Non Operating Income of -$15.0 million for Q1 2015, down 167.56% year-over-year from $22.2 million in Q1 2014, and down 70.88% on a QoQ basis from -$8.8 million in Q4 2014.
Biogen (BIIB) Other Non Operating Income (2009 - 2015) Analysis & Trends
Biogen (BIIB) has reported Other Non Operating Income for 7 consecutive years, with -$15.0 million the latest figure, recorded in Q1 2015.
- In Q1 2015, Other Non Operating Income fell 167.56% year-over-year to -$15.0 million; the TTM figure through Mar 2015 stood at -$35.2 million (down 35.1% YoY), while the FY2016 annual figure was -$217.4 million, down 75.75% from the prior year.
- Other Non Operating Income came in at -$15.0 million for Q1 2015 at Biogen, down from -$8.8 million in the prior quarter.
- The five-year high for Other Non Operating Income was $15.1 million in Q1 2012, with the low at -$16.3 million in Q3 2014.
- Average Other Non Operating Income over 5 years is -$5.9 million, with a median of -$5.6 million recorded in 2014.
- Across the five-year window, Other Non Operating Income sank 453.49% in 2013 and soared 146.61% in 2014, its largest moves.
- Year by year, Other Non Operating Income stood at -$4.0 million in 2011, then slumped by 259.68% to -$14.3 million in 2012, then jumped by 62.39% to -$5.4 million in 2013, then slumped by 63.16% to -$8.8 million in 2014, then plunged by 70.88% to -$15.0 million in 2015.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$15.0 million, -$8.8 million, and -$16.3 million for Q1 2015, Q4 2014, and Q3 2014 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2015 | -14.99 Mn |
| Dec 31, 2014 | -8.77 Mn |
| Sep 30, 2014 | -16.29 Mn |
| Jun 30, 2014 | 4.86 Mn |
| Mar 31, 2014 | -5.60 Mn |
| Dec 31, 2013 | -5.38 Mn |
| Sep 30, 2013 | -4.64 Mn |
| Jun 30, 2013 | -10.43 Mn |
| Mar 31, 2013 | -14.46 Mn |
| Dec 31, 2012 | -14.29 Mn |
| Sep 30, 2012 | -4.55 Mn |
| Jun 30, 2012 | 2.95 Mn |
| Mar 31, 2012 | 15.14 Mn |
| Dec 31, 2011 | -3.97 Mn |
| Sep 30, 2011 | -7.73 Mn |
| Dec 31, 2010 | -4.70 Mn |
| Sep 30, 2010 | -6.90 Mn |
| Jun 30, 2010 | 1.00 Mn |
| Mar 31, 2010 | -8.40 Mn |
| Dec 31, 2009 | 6.40 Mn |